Beta

Heartsciences inc.HSCS.US Overview

US StockHealthcare
(No presentation for HSCS)
OverviewAI AnalysisFinancialsFinancial ForecastStock SentimentalInstitutionsTradingView Chart

Ticker

Value

empty

There is no following symbol in this watchlist.

HSCS AI Insights

HSCS Overall Performance

HSCS AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

HSCS Recent Performance

-0.50%

Heartsciences inc.

-1.10%

Avg of Sector

-0.49%

S&P500

HSCS PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

Check HSCS's Trend

HSCS Key Information

HSCS Valuation Metrics

HSCS Profile

Heart Test Laboratories, Inc., a medical technology company, provides cardiovascular diagnostic devices. The company offers MyoVista wavECG, a resting 12-lead electrocardiograph (ECG) to provide diagnostic information related to cardiac dysfunction, as well as conventional 12-lead resting ECG information. It serves clinics, doctor's offices, urgent care centers, and hospitals. The company was incorporated in 2007 and is headquartered in Southlake, Texas.

Price of HSCS

HSCS FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

HSCS Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-3.92
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
753.10
PB Ratio
2.45
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
57.92%
Net Margin
-97880.97%
Revenue Growth (YoY)
-41.03%
Profit Growth (YoY)
-50.48%
3-Year Revenue Growth
-100.00%
3-Year Profit Growth
-100.00%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-3.92
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
753.10
PB Ratio
2.45
Price-to-FCF
-
Gross Margin
57.92%
Net Margin
-97880.97%
Revenue Growth (YoY)
-41.03%
Profit Growth (YoY)
-50.48%
3-Year Revenue Growth
-100.00%
3-Year Profit Growth
-100.00%

  • When is HSCS's latest earnings report released?

    The most recent financial report for Heartsciences inc. (HSCS) covers the period of 2026Q3 and was published on 2026/01/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating HSCS's short-term business performance and financial health. For the latest updates on HSCS's earnings releases, visit this page regularly.

  • How much debt does HSCS have?

    As of the end of the reporting period, Heartsciences inc. (HSCS) had total debt of 3.87M, with a debt ratio of 0.51. Short-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does HSCS have?

    At the end of the period, Heartsciences inc. (HSCS) held Total Cash and Cash Equivalents of 3.4M, accounting for 0.45 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is HSCS's EPS continuing to grow?

    According to the past four quarterly reports, Heartsciences inc. (HSCS)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.63. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of HSCS?

    Heartsciences inc. (HSCS)'s Free Cash Flow (FCF) for the period is -1.45M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 10.31% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of HSCS?

    The latest valuation data shows Heartsciences inc. (HSCS) has a Price-To-Earnings (PE) ratio of -1 and a Price/Earnings-To-Growth (PEG) ratio of 0.05. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.